Pharmaceutical value-added industrial output growth (half year)

STO-REC-STATYABFYJT1 Official
6.4%

China · as of 30 Jun 2026

Pharmaceutical value-added industrial output growth in China (half year) came in at 6.4% as of 30 June 2026 (State Council).

Original source
Publisher
State Council
Authority tier
T1 Official
Locator
Value of China's innovative drug out-licensing deals hit new high in H1
Retrieved
17 Sep 2026
Status
Verified

What the source says

From January to June, value-added industrial output of major pharmaceutical enterprises rose 6.4 percent year on year, with biopharmaceuticals posting double-digit growth.

Verbatim extraction verified: The figure 6.4% is directly attested in the quoted passage (Value of China's innovative drug out-licensing deals hit new high in H1).

The figure above was extracted from this passage. If it does not match, the extraction is wrong and we want to know.

Cite this figure

Published under CC BY 4.0. Attribute the original publisher; the citations below do that for you and link to this permanent record.

APA
State Council of China. (2026). Value of China's innovative drug out-licensing deals hit new high in H1. Retrieved September 17, 2026, from https://english.www.gov.cn/archive/statistics/202607/20/content_WS6a5de696c6d00ca5f9a0c514.html. Via StatOrigin, https://statorigin.org/stat/stat_YABFYJCS9AQZNP55ZF5P6GHRNW
MLA
State Council of China. "Value of China's innovative drug out-licensing deals hit new high in H1." 2026, https://english.www.gov.cn/archive/statistics/202607/20/content_WS6a5de696c6d00ca5f9a0c514.html. Accessed 17 Sept. 2026 via StatOrigin, https://statorigin.org/stat/stat_YABFYJCS9AQZNP55ZF5P6GHRNW.
Chicago
State Council of China. "Value of China's innovative drug out-licensing deals hit new high in H1." 2026. https://english.www.gov.cn/archive/statistics/202607/20/content_WS6a5de696c6d00ca5f9a0c514.html. Accessed September 17, 2026. Cited from StatOrigin, https://statorigin.org/stat/stat_YABFYJCS9AQZNP55ZF5P6GHRNW.
BibTeX
@misc{statecouncil2026pharmaceutical6ghrnw, author = {{State Council of China}}, title = {Value of China's innovative drug out-licensing deals hit new high in H1}, year = {2026}, howpublished = {StatOrigin, https://statorigin.org}, url = {https://statorigin.org/stat/stat_YABFYJCS9AQZNP55ZF5P6GHRNW}, note = {Original source: https://english.www.gov.cn/archive/statistics/202607/20/content\_WS6a5de696c6d00ca5f9a0c514.html. Accessed September 17, 2026.} }

Provenance and verification

Everything needed to check this number yourself, without taking our word for it.

Chain of Custody · Verification Audit
Record: STO-REC-STATYABFYJ T1 Official

Primary Source

Publisher
State Council of China · homepage ↗
Authority tier
Tier 1 · Multilateral Official
Report
Value of China's innovative drug out-licensing deals hit new high in H1
Type
Press release
Published
Locator
Value of China's innovative drug out-licensing deals hit new high in H1
Retrieved
17 September 2026
Link status
Reachable (HTTP 200)
Report licence
See source

Verification & Integrity

Audit status
Verified
Review protocol
Editorial review
Checked on
17 September 2026
Last revision
17 September 2026
Archival URI
/stat/stat_YABFYJCS9AQZNP55ZF5P6GHRNW